CD276 and neoplasm: Based on these findings, B7-H3 appears to be an attractive target antigen for immunotherapy, as (i) B7-H3 expression is almost exclusively limited to tumor tissue, (ii) expression on tumor vasculature allows for additional targeting of both cancer cells and vasculature, allowing for dual mode of anticancer action and (iii) blocking of B7-H3 might reduce its immunosuppressive properties.